Ion Torrent competitors

Adelene Perkins serves as Infinity’s chief executive officer and Infinity’s chair, a position she has held since 2012. She was named chief executive officer and elected to the Board of Directors in 2009. Before serving as CEO, Ms. Perkins served as Infinity’s President, a position she held since 2008. Ms. Perkins joined Infinity in June 2002 as executive vice president and chief business officer. Ms. Perkins joined Infinity from TransForm Pharmaceuticals where she served as vice president of business and corporate development and an early member of the management team that built the company prior to its acquisition by J&J. Prior to TransForm, from 1992-1999, she was at Genetics Institute, now a unit of Pfizer, where she was vice president of emerging businesses and the co-founder and general manager of the DiscoverEase™ business unit. She also formed and served as chief executive officer of MetaMorphix, a joint venture between Genetics Institute and Johns Hopkins University. She joined Genetics Institute in corporate and business development where she led corporate and product strategy initiatives. From 1985-1992, Ms. Perkins worked at Bain & Company, an international strategy consulting firm, where she provided strategic and operational advice to clients in the healthcare industry. Ms. Perkins received her M.B.A. from Harvard Business School and her B.S. in chemical engineering from Villanova University. In addition to chairing the Infinity (NASDAQ: INFI) Board, she is on the Boards of Bruker Corporation (NASDAQ: BRKR), Massachusetts General Hospital, BIO (Biotechnology Industry Organization), the Massachusetts Biotechnology Council, and is the vice chairman of the Board of Project Hope. She is a past member of the Boards of Padlock Therapeutics, prior to its acquisition by Bristol-Myers Squibb, and the Massachusetts Life Science Center.

James C. Powers was appointed full-time CEO in February 2009. Prior to joining HemoShear, Powers spent 20 years as an executive in the pharmaceutical R&D services sector, 18 of those with global firm PRA International where he grew the company from a niche services provider to a global clinical trials management organization of more than 3,000 employees. Powers launched PRA’s oncology therapeutic focus, a market in which PRA continues to be a leader, and was instrumental in strategic planning and eight acquisitions. PRA International had a successful IPO in 2004. Powers was an advisor to the Coulter Translational Research Partnership in Biomedical Engineering at the University of Virginia where he met Drs. Blackman and Wamhoff. Powers currently serves on the boards of Gene Solutions, LLC, and Virginia BIO and is Chairman of the Virginia Bioscience Foundation. Powers received a BS in Administration and Management Science from Carnegie-Mellon University.

Chris Cappello is a President/CEO at Pharmajet and Board Member at Pharmajet. He has worked as Chief Operating Officer at Pharmajet. Chris studied at Colorado State University.

Richard S. Egosi is the Executive Vice President, Chief Legal Officer and Company Secretary for Teva Pharmaceuticals, a multinational pharmaceutical company. Mr. Egosi is a member of the Teva Executive Committee and oversees the legal, compliance, intellectual property and public policy functions for Teva. He has worked both domestically and abroad for Teva Pharmaceuticals since 1995 holding his current position since 2010, and as Sr. Vice President and General Counsel of the Americas from 2000 to 2010. Prior to joining Teva Pharmaceuticals, Mr. Egosi was in private practice in Atlanta, Georgia, specializing in both corporate law and general litigation from 1988 to 1994. Mr. Egosi is a member of numerous trade associations and local non-profit organizations in both Pennsylvania and New York and is a general partner in several real estate and commercial business ventures. Mr. Egosi is a 1984 cum laude graduate of Clemson University, South Carolina, with a BS in Economics and a 1988 graduate of Emory University, Atlanta, Georgia, with an MBA and JD degree, earning the distinction of The Order of the Coif and served as a member of the Emory Law Review.

Qasim Rizvi is the Senior Vice President of Operations and Chief Commercial Officer at Kiniksa Pharmaceuticals.